EHA 2015 | SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma

Name: SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma
Uploaded: 2015-06-12T00:00:00.000Z
Duration: 1 min 33 s
Description: Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the update of the phase 3 SABRINA trial that was presented at the 20th Congress of the European Hematology Association (EHA). SABRINA evaluated subcutaneous versus intravenous rituximab in patients with previously untreated follicular lymphoma.

Andrew Davies • 12 Jun 2015

EHA 2015

Follicular Lymphoma Antibodies Rituximab

Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the update of the phase 3 SABRINA trial that was presented at the 20th Congress of the European Hematology Association (EHA). SABRINA evaluated subcutaneous versus intravenous rituximab in patients with previously untreated follicular lymphoma.